Navigation Links
Origen publishes in Nature a robust and versatile method for creating transgenic chickens

Origen Therapeutics announced today that it has succeeded in developing a robust and versatile technology for genetically modifying chickens that, for the first time, puts avian transgenics on a par with transgenic mice. The company made the announcement in conjunction with the publication of an article this week by Origen scientists and a collaborator from the University of California, Davis on its transgenic technology in the journal Nature.

Using the new technology, Origen can, in principle, make any genetic modification desired to the chicken genome, including the insertion of genetic elements for the production of human therapeutics and the modification of the chicken immune system to produce novel human sequence polyclonal antibodies. Moreover, the new technology opens up the possibility of producing chickens with enhanced agronomic traits, including resistance to avian flu.

"This research breakthrough came when we turned our attention to primordial germ cells, the precursor cells to sperm and eggs," said Marie-Cecile van de Lavoir, senior scientist at Origen. "These cells ?which we are the first to successfully culture without changing their commitment -- proved to be the key to introducing genetic elements into the chicken genome. As a result, we can now take transgene designs that work well in model systems and breed flocks of birds depositing therapeutic proteins in their eggs. The use of primordial germ cells, the ease of producing small or large flocks of chickens, and the existing infrastructure for rearing chickens and processing eggs means that therapeutic proteins can now be produced efficiently and economically in the eggs of chickens."

Origen scientists first demonstrated the potential for the production of human protein therapeutics in chicken eggs in August 2005, when company scientists published in Nature Biotechnology the production of human sequence monoclonal antibodies having greatly enhanced cancer killing activity co mpared to antibodies produced via conventional methods.

"While that earlier research was done with chimeric chickens, it demonstrated the enormous opportunities that transgenic chickens hold as a therapeutics production system," said Robert Kay, Ph.D. Origen Therapeutics president and chief executive officer. "We believe a transgenic chicken system offers a number of advantages over either plant or other transgenic animal systems for protein production. Besides the ability to produce antibodies with enhanced cell killing properties, the time from antibody identification to production in eggs is a matter of months, the purification of proteins from eggs is relatively simple, and good manufacturing practices have long been established for vaccine production in chicken eggs. Moreover, the overall cost of facility and operations is a fraction of that associated with fermentation methods of manufacture. The ability to readily create transgenic chickens through this technology, and then to scale up production through conventional breeding further adds to the practicality of this technology for large-scale production of therapeutic proteins."

In the early embryo, only a few cells known as primordial germ cells (PGCs) become sperm or eggs in the adult animal. Previous attempts to culture PGCs from mice and humans produced embryonic germ cells that look and act like embryonic stem cells. The chicken is the first species from which PGCs can be isolated, cultured and genetically modified while retaining their commitment to the germ line. Additionally, under certain conditions, Origen scientists could induce the PGCs in vitro to differentiate into embryonic germ cells that contribute to somatic tissue.

"As well as the practical applications of this work, the ability to engineer PGCs and influence them to commit in cell culture to either the germline or the somatic lineages provides a very useful new tool for understanding some of the earliest and most fu ndamental events in developmental biology on a molecular level," said Robert J. Etches, Ph.D., D.Sc., vice president of research at Origen Therapeutics.

"This work addresses a major biomedical issue -- how to produce antibody-based medicines in an easy, cost-effective way," said Matthew E. Portnoy, Ph.D., of the National Institute of General Medical Sciences, which partially funded the research. "Beyond that, it will help researchers understand stem cell biology and development --something that holds great value for all sorts of basic studies. This is exactly the kind of result we hope for through our Small Business Innovation Research Program."


'"/>

Source:jkureczka@comcast.net


Related biology news :

1. PLoS Medicine publishes first trial of effect of male circumcision on HIV infection
2. DOE publishes research roadmap for developing cleaner fuels
3. Nature provides inspiration for important new adhesive
4. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
5. Rewind, please: Nature paper shows that cell division is reversible
6. Natures process for nitrogen fixation caught in action
7. Towards precise classification of cancers based on robust gene functional expression profiles
8. Spleen may be source of versatile stem cells
9. Anemone genes reveal versatile building blocks for body plans
10. Engineer ramps up protein production, develops versatile viral spheres
11. Color-blind method opens new doors in DNA sequencing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... This report analyzes the Global market for Human ... forecasts are provided for the period 2014 through 2022. Market data ... The report profiles 25 companies including many key and niche ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... material that exhibits both viscous and elastic characteristics when deformed, which is identical ... exhibits properties to gently absorb compressive forces and return to its natural state ...
(Date:3/23/2017)... Colo. , March 23, 2017  GlobeImmune, Inc. ... agreement for the sale of 12,835,490 shares of its ... NantWorks  ecosystem of companies. In connection with the sale of ... $100,000 in cash and issue to GlobeImmune 200,000 shares, ... stock. "We are pleased to enter ...
(Date:3/23/2017)... According to a report by Transparency Market ... due to the presence of a large pool of participants; however, ... , and Sigma-Aldrich, compete with each other in this market. With ... than 76% of this market in 2016.  ... As of now, a large number of ...
Breaking Biology Technology: